Immunization Schedule

• 

  Subject Areas on Research

  • A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. 
  • A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. 
  • A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children. 
  • A major barrier to universal hepatitis B immunization of infants. 
  • A shortened interval between vaccinations with the trivalent inactivated influenza vaccine increases responsiveness in the aged. 
  • Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens. 
  • Addressing the vaccine confidence gap. 
  • Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2014. 
  • Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older--United States, 2015. 
  • Analysis of factors influencing vaccine uptake: perspective from Spain. 
  • Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group. 
  • Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial. 
  • Cocooning infants: Tdap immunization for new parents in the pediatric office. 
  • Comparative study of the immunogenicity and safety of two dosing schedules of hepatitis B vaccine in neonates. 
  • Comparison of acellular pertussis-diphtheria-tetanus toxoids and Haemophilus influenzae type b vaccines administered separately vs. combined in younger vs. older toddlers. 
  • Comparison of the epidemiology and cost of Haemophilus influenzae type b disease in five western countries. 
  • Completeness of Human Papilloma Virus Vaccination: A Systematic Review. 
  • Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. 
  • Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. 
  • Cross-reactivity of HIV vaccine responses and the microbiome. 
  • DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies. 
  • Development and application of a multiplex assay for the simultaneous measurement of antibody responses elicited by common childhood vaccines. 
  • Effectiveness of measles vaccination and vitamin A treatment. 
  • Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus. 
  • Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins. 
  • Evaluating human papillomavirus vaccination programs. 
  • Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals. 
  • Family physician acceptance of universal hepatitis B immunization of infants. 
  • HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. 
  • HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. 
  • Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab). 
  • Harmony on the second dose of measles vaccine. 
  • Human lymphocyte proliferation responses following primary immunization with rabies vaccine as neoantigen. 
  • Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. 
  • Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. 
  • Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. 
  • Immunizations for preteens. 
  • Improving preventive service delivery through office systems. 
  • Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. 
  • Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming? 
  • Kinetics of TCR use in response to repeated epitope-specific immunization. 
  • Large injection site reactions after a second dose of varicella vaccine. 
  • Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120. 
  • Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. 
  • Maternal determinants of timely vaccination coverage among infants in rural Bangladesh. 
  • Melanoma patient antibody responses to melanoma tumor-associated antigens defined by murine monoclonal antibodies. 
  • Missed opportunities for adolescent vaccination, 2006-2011. 
  • Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge. 
  • On-time vaccine receipt in the first year does not adversely affect neuropsychological outcomes. 
  • Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents. 
  • Pediatricians' preferences for infant meningococcal vaccination. 
  • Perspective on live varicella vaccine. 
  • Poliovaccine policy--time for a change. 
  • Practical Approaches to Optimize Adolescent Immunization. 
  • Prenatal immunization education the pediatric prenatal visit and routine obstetric care. 
  • Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season. 
  • Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season. 
  • Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) -- United States, 2014-15 influenza season. 
  • Randomized trial to determine safety and immunogenicity of two strategies for hepatitis B vaccination in healthy urban adolescents in the United States. 
  • Reactions of pediatricians to a new Centers for Disease Control recommendation for universal immunization of infants with hepatitis B vaccine. 
  • Recommendations for Prevention and Control of Influenza in Children, 2018-2019. 
  • Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2018. 
  • Risk of fever and sepsis evaluations after routine immunizations in the neonatal intensive care unit. 
  • SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. 
  • Safety and Immunogenicity of DTaP5-IPV Compared With DTaP5 Plus IPV as the Fifth Dose in Children 4-6 Years of Age. 
  • Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules. 
  • Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults. 
  • Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. 
  • Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. 
  • Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. 
  • Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida. 
  • Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children. 
  • Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. 
  • Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen. 
  • Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. 
  • The Need to Optimize Adolescent Immunization. 
  • Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers. 
  • Timing of retroviral infection influences anamnestic immune response in vaccinated primates. 
  • Trivalent inactivated influenza virus vaccine given to two-month-old children: an off-season pilot study. 
  • Underimmunization at discharge from the neonatal intensive care unit. 
  • Update on immunizations in adults. 
  • Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) - United States, 2018-19 Influenza Season. 
  • Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. 
  • Vaccine coverage and adherence to EPI schedules in eight resource poor settings in the MAL-ED cohort study. 
  • Vaccine safety: medical contraindications, myths, and risk communication. 
  • Workshop on immunizations in older adults: identifying future research agendas. 
• 

  Keywords of People

  • Cunningham, Coleen Kathryn, Professor of Pediatrics, Pathology
  • Ferrari, Guido, Associate Professor of Surgery, Molecular Genetics and Microbiology
  • Kelsoe, Garnett H., James B. Duke Professor of Immunology, Immunology
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Professor of Experimental Surgery, in the School of Medicine, Immunology